Navigation Links
Xeloda in Medical News

Drug Xeloda as effective as Traditional Chemotherapy

According to Drugmaker Roche Holding AG Xeloda oral chemotherapy is proving to be as effective as traditional chemotherapy to treat advanced stomach cancer//. Data from a Phase III study which will be presented at an American Society of Clinical Oncology meeting (ASCO) has shown that Xeloda, al...

Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment

...nn-La Roche filed a lawsuit April 8 in the U.S. District Court for the District of New Jersey alleging infringement of U.S. Patent No. 5,472,949. xeloda Tablets, 150 mg and 500 mg, had approximately $447 million in sales for the 12 months ending Dec. 31, 2008, according to IMS Health. Currently, Mylan ...

Chinese Colorectal Cancer Drug Market Will More Than Double by 2012

...rongest drivers of the Chinese colorectal drug market during the next five years," stated Jing Wu, M.S., MBA. "We also expect a high uptake of Roche's xeloda -- an oral pro-drug of 5-fluorouracil (5-FU) -- due to its delivery advantage over intravenous 5-FU and its inclusion on the National Reimbursement Dr...

Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium

...etastatic breast cancer who were treated with oral xeloda monotherapy compared with vinorelbine monotherapy ...hat metastatic breast cancer patients treated with xeloda monotherapy had statistically significant lower to...ina metastatic breast cancer patients treated with xeloda or taxane monotherapy. -- Dec. 14, 7:00 to...

Pharsight to Present on Oncology Modeling and Simulation at PAGE Annual Meeting

...ology case studies during a dedicated conference session on applications in model-based development: -- June 18: A Modeling Framework to Simulate xeloda Dose Intensity and Survival in Colorectal Cancer. Dr. Claret will present this case study as part of an oral conference session on the strat...

Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers

...ved in women with platinum-resistant disease to standard chemotherapy agents such as liposomal doxorubicin; topotecan; hexamethylmelamine; oral VP-16; xeloda and gemcitabine. One patient had a partial response to paclitaxel. The overall response rate in this subgroup was 2 percent. Sixty-one (62 percent) ...

Many More Patients Can Now Benefit from Avastin's Proven Survival Benefits

...se (CHMP) positive recommendations for the extended use of both Avastin and xeloda in December 2007. *The final EC decision on Xeloda for its extended use is ...d fluoropyrimidine based chemotherapy and also allows for combinations with xeloda or oxaliplatin. Avastin formerly could only be used in combination with IV ...

Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle

...he XeNA results demonstrate the potential for oral xeloda to serve as the cornerstone of combination chemoth...fected breast after preoperative administration of xeloda and Taxotere for HER2-negative patients and in com...treatment regimen. HER2-negative patients received xeloda 825 mg/m2 twice a day for 14 days with seven days ...

Tablet is better all round for cancer patients

...s can be unpleasant. The oral chemotherapy drug xeloda (capecitabine) offers fewer side-effects and less ...rch showed that about 71 percent of patients given xeloda were still alive after five years, compared to 68 ...ancer surgery. It found that patients treated with xeloda spent 85 percent less time with their doctor or at...

GlaxoSmithKline’s Tykerb is to Be Started Earlier in Breast Cancer, Study Find

... Phase III study has shown that GlaxoSmithKline's Tykerb along with Roche's xeloda is far better than xeloda alone in women with HER2// positive advanced breast cancer, where the disea...
Xeloda in Medical Technology

New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer

BASEL, Switzerland, Dec. 10 /PRNewswire/ -- New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue to offer new and better treatment options for breast cancer patients al...

New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer

...ue and importance of combination therapy with oral xeloda for the thousands of patients with this insidious ... "We're excited to see the continued promise of xeloda as a cornerstone of combination cancer treatments,...eting also will feature five additional Roche U.S. xeloda abstracts, including a second XELOX abstract. All ...

Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer

...well tolerated for CRC patients with yet further chemotherapy combinations, xeloda (capecitabine) and irinotecan (XELIRI) and xeloda and oxaliplatin (XELOX). This data reinforces that Avastin is first choice ...

Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting

...ational, seven-days-on/seven-days-off (7-on/7-off) xeloda regimen versus the current standard xeloda dosing of fourteen-days-on/seven-days-off (14-on/7...proved tumor growth inhibition with the 7-on/7-off xeloda regimen; results support clinical testing of this ...

Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer

... providing a potential alternative to the standard xeloda dosing of 14 days on and seven days off (14-on/7-o...dule." Efficacy of the 7-on/7-off schedule using xeloda is being determined in a Phase II clinical trial p...as applied to determine that the maximum impact of xeloda treatment in breast cancer patients occurs after s...

Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium

... - U.S. Data Highlights Oral xeloda versus Standard Infusional Chemotherapy ...ty profile and usage patterns of therapy with oral xeloda to that of intravenous fluorouracil (5-FU) therapy...nical efficacy and tolerability results of a novel xeloda regimen (7/7, or 7 days on, 7 days off) using high...

Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting

... Results show five-year overall survival rates for xeloda at 71.4 percent compared to 68.4 percent in the 5-... at the meeting from a previous analysis show that xeloda is also comparable to 5- FU/LV with respect to dis...r overall survival data provide further proof that xeloda can be a safe and effective alternative to the cur...

Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer

...ble metastatic disease received Avastin in combination with standard first line chemotherapy; the most common regimens were FOLFOX, XELOX, FOLFIRI and xeloda (capecitabine). The dose of Avastin used was equivalent to 2.5 mg/kg/week (5 mg/kg every 2 weeks with 5-FU-based regimens and 7.5 mg/kg every 3 weeks ...

Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium

...the XeNA (Xeloda in NeoAdjuvant) trial, a study of xeloda and docetaxel with or without Herceptin in patient...ndings that validate efficacy and cost benefits of xeloda in breast cancer patients. -- Poster No. A54, [Ge...oche's commitment to exploring the expanded use of xeloda in combination with new therapies. About...

Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium

...ta abstracts about its oral chemotherapy treatment xeloda have been accepted for presentation at the 2007 Br...the XeNA (Xeloda in NeoAdjuvant) trial, a study of xeloda and docetaxel with or without Herceptin in patient...ndings that validate efficacy and cost benefits of xeloda in breast cancer patients. -- Poster No. A54, [Ge...
Other Tags
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been a licensed ... "I specialize in manual therapy, and my invention will provide headache sufferers a ... additional muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates ...
(Date:8/29/2015)... ... ... Next weekend is Labor Day weekend, the last bash of the season ... year). For IT security personnel, it should also mark the perfect time to make ... than a simple headache. , Joe Caruso, founder and CEO-CTO of Global Digital ...
(Date:8/29/2015)... TX (PRWEB) , ... August 29, 2015 , ... ... allows the company to freely market and sell Arterosil and Arterosil HP, and ... Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment ... position they are applying for, they are unable to pass the initial drug test ... drug testing policies in order to be able to hire long-term, skilled talent. (1) ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a non-invasive ... two years, the longest of any cellulite reduction system currently on the market. ... solution for their cellulite, according to Dr. Robert Weiss, director of the premier MD ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
(Date:8/4/2015)... 2015  AMRI (NASDAQ: AMRI ) today reported financial and ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 % ... a $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial ...
(Date:7/31/2015)... juli 2015 Den 10. internationale konference om ... den 22. - 25. oktober i Shenzhen ... 10-års fødselsdag i år. Siden starten i 2006 er ... på ,omik,-feltet, og er en af de mest dynamiske, ... fokuserer på nylige gennembrud og fremskridt inden for ,omik,-forskning, ...
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
Other Contents